Niagen Bioscience (NAGE) Net Cash Flow (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Net Cash Flow data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 83.93% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $10.9 million, a 61.02% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, up 16.11% from the prior year.
• Net Cash Flow for Q1 2026 stood at $1.8 million, up from $523000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for NAGE reached as high as $12.3 million in Q4 2024 and fell as low as -$7.2 million in Q1 2022.
• Historically, Net Cash Flow has averaged $2.3 million across 5 years, with a median of $1.8 million in 2026.
• Across the five-year window, Net Cash Flow plunged 125.81% in 2022 and jumped 4465.0% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $7.2 million in 2022, then sank by 92.31% to $552000.0 in 2023, then soared by 2121.38% to $12.3 million in 2024, then slumped by 95.73% to $523000.0 in 2025, then jumped by 236.71% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $1.8 million in Q1 2026, $523000.0 in Q4 2025, and $3.8 million in Q3 2025.